Knockout of c-Cbl/Cbl-b slows c-Met trafficking resulting in enhanced signaling in corneal epithelial cells.

Kate Tarvestad-Laise, Brian P Ceresa
Author Information
  1. Kate Tarvestad-Laise: Department of Pharmacology and Toxicology (KTL, BPC) and Department of Ophthalmology and Vision Sciences (BPC), University of Louisville, Louisville, Kentucky, USA.
  2. Brian P Ceresa: Department of Pharmacology and Toxicology (KTL, BPC) and Department of Ophthalmology and Vision Sciences (BPC), University of Louisville, Louisville, Kentucky, USA. Electronic address: brian.ceresa@louisville.edu.

Abstract

In many cell types, the E3 ubiquitin ligases c-Cbl and Cbl-b induce ligand-dependent ubiquitylation of the hepatocyte growth factor (HGF)-stimulated c-Met receptor and target it for lysosomal degradation. This study determines whether c-Cbl/Cbl-b are negative regulators of c-Met in the corneal epithelium (CE) and if their inhibition can augment c-Met-mediated CE homeostasis. Immortalized human corneal epithelial cells were transfected with Cas9 only (Cas9, control cells) or with Cas9 and c-Cbl/Cbl-b guide RNAs to knockout each gene singularly (-c-Cbl or -Cbl-b cells) or both genes (double KO [DKO] cells) and monitored for their responses to HGF. Cells were assessed for ligand-dependent c-Met ubiquitylation via immunoprecipitation, magnitude, and duration of c-Met receptor signaling via immunoblot and receptor trafficking by immunofluorescence. Single KO cells displayed a decrease in receptor ubiquitylation and an increase in phosphorylation compared to control. DKO cells had no detectable ubiquitylation, had delayed receptor trafficking, and a 2.3-fold increase in c-Met phosphorylation. Based on the observed changes in receptor trafficking and signaling, we examined HGF-dependent in vitro wound healing via live-cell time-lapse microscopy in control and DKO cells. HGF-treated DKO cells healed at approximately twice the rate of untreated cells. From these data, we have generated a model in which c-Cbl/Cbl-b mediate the ubiquitylation of c-Met, which targets the receptor through the endocytic pathway toward lysosomal degradation. In the absence of ubiquitylation, the stimulated receptor stays phosphorylated longer and enhances in vitro wound healing. We propose that c-Cbl and Cbl-b are promising pharmacologic targets for enhancing c-Met-mediated CE re-epithelialization.

Keywords

References

  1. Exp Eye Res. 1997 Apr;64(4):501-4 [PMID: 9227267]
  2. Exp Eye Res. 2020 Aug;197:108089 [PMID: 32553485]
  3. Mol Cell Biol. 1997 Feb;17(2):799-808 [PMID: 9001234]
  4. Mol Cancer Ther. 2011 Jan;10(1):169-77 [PMID: 21220499]
  5. Physiol Rev. 2002 Apr;82(2):373-428 [PMID: 11917093]
  6. Prog Retin Eye Res. 2015 Nov;49:17-45 [PMID: 26197361]
  7. Anal Biochem. 2013 Sep 15;440(2):227-36 [PMID: 23743150]
  8. Invest Ophthalmol Vis Sci. 1996 Apr;37(5):727-39 [PMID: 8603858]
  9. Cornea. 1996 Sep;15(5):505-16 [PMID: 8862928]
  10. Mater Sci Eng C Mater Biol Appl. 2021 Jan;120:111790 [PMID: 33545916]
  11. Biol Pharm Bull. 2004 Jun;27(6):781-5 [PMID: 15187417]
  12. J Invest Dermatol. 2003 Feb;120(2):335-43 [PMID: 12542542]
  13. Mol Cell Biol. 2009 Sep;29(17):4798-811 [PMID: 19546233]
  14. J Biol Chem. 2007 Jun 8;282(23):16764-75 [PMID: 17449471]
  15. J Biol Chem. 2009 May 1;284(18):12110-24 [PMID: 19265192]
  16. Invest Ophthalmol Vis Sci. 1999 Sep;40(10):2185-90 [PMID: 10476782]
  17. FASEB J. 2003 Feb;17(2):268-70 [PMID: 12475893]
  18. EMBO J. 1991 Oct;10(10):2867-78 [PMID: 1655405]
  19. J Hypertens. 2010 Dec;28(12):2454-61 [PMID: 20842048]
  20. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(6):588-610 [PMID: 20551596]
  21. Invest Ophthalmol Vis Sci. 1998 Apr;39(5):699-704 [PMID: 9538875]
  22. Invest Ophthalmol Vis Sci. 2014 May 01;55(5):2870-80 [PMID: 24722692]
  23. Oncogene. 2007 Oct 25;26(49):6968-78 [PMID: 17486068]
  24. Science. 1990 Feb 23;247(4945):962-4 [PMID: 2305263]
  25. Curr Opin Cell Biol. 2000 Apr;12(2):204-10 [PMID: 10712919]
  26. J Neurosci Res. 1996 Mar 01;43(5):554-64 [PMID: 8833090]
  27. Biochim Biophys Acta. 2013 Jan;1833(1):122-39 [PMID: 23085373]
  28. Mol Cell Endocrinol. 2013 Dec 5;381(1-2):188-97 [PMID: 23933150]
  29. Invest Ophthalmol Vis Sci. 1993 Nov;34(12):3320-8 [PMID: 8225867]
  30. Invest Ophthalmol Vis Sci. 1993 Jul;34(8):2544-61 [PMID: 8392040]
  31. Case Rep Ophthalmol Med. 2012;2012:379132 [PMID: 23320223]
  32. J Clin Oncol. 2011 Aug 10;29(23):e678-9 [PMID: 21690478]
  33. Traffic. 2007 Dec;8(12):1854-1872 [PMID: 17944804]
  34. J Biol Chem. 2008 Jul 25;283(30):21267-77 [PMID: 18495663]
  35. Sci Signal. 2015 Apr 28;8(374):ra40 [PMID: 25921289]
  36. Mol Ther. 2017 Aug 2;25(8):1881-1888 [PMID: 28502469]
  37. Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10608-13 [PMID: 15249655]
  38. Ophthalmology. 2012 Sep;119(9):1798-802 [PMID: 22584020]
  39. J Ophthalmol. 2015;2015:852986 [PMID: 26697215]
  40. J Biol Chem. 2004 Dec 17;279(51):52835-9 [PMID: 15466866]
  41. Oncogene. 2001 May 17;20(22):2761-70 [PMID: 11420688]
  42. Nature. 2002 Mar 14;416(6877):187-90 [PMID: 11894096]
  43. Biochem Biophys Rep. 2021 Mar 03;26:100973 [PMID: 33718632]
  44. Am J Respir Cell Mol Biol. 2002 May;26(5):525-33 [PMID: 11970903]
  45. Neuroreport. 2001 May 25;12(7):1403-7 [PMID: 11388419]
  46. Mol Cell Biol. 2005 Nov;25(21):9632-45 [PMID: 16227611]
  47. Curr Opin Chem Biol. 2013 Feb;17(1):59-65 [PMID: 23339974]
  48. Biochem Biophys Res Commun. 1995 Aug 4;213(1):32-9 [PMID: 7639752]
  49. Biomedicines. 2015 Jan 15;3(1):46-70 [PMID: 28536399]
  50. Mol Cell Biol. 2007 Aug;27(16):5686-98 [PMID: 17548467]
  51. Mol Cell Biol. 2012 Sep;32(18):3610-23 [PMID: 22778134]
  52. Ophthalmology. 2021 Jun;128(6):813-815 [PMID: 32739177]
  53. Mol Cell. 2001 Nov;8(5):995-1004 [PMID: 11741535]
  54. Exp Eye Res. 2014 Apr;121:178-93 [PMID: 24607489]
  55. Mol Cell Biol Res Commun. 1999 Aug;2(2):111-8 [PMID: 10542134]
  56. Cornea. 2009 Jul;28(6):706-7 [PMID: 19512896]
  57. J Clin Invest. 1998 May 1;101(9):1827-34 [PMID: 9576745]
  58. Gastroenterology. 1997 Dec;113(6):1858-72 [PMID: 9394725]
  59. Cancer Cell. 2003 Jun;3(6):519-23 [PMID: 12842080]
  60. Kidney Int. 2000 Mar;57(3):937-48 [PMID: 10720947]
  61. Cornea. 2008 Jun;27(5):612-4 [PMID: 18520515]
  62. Eur J Biochem. 1992 Mar 1;204(2):857-64 [PMID: 1311683]
  63. FEBS Lett. 2011 Jun 23;585(12):1741-7 [PMID: 21570973]
  64. J Biol Chem. 2004 Jul 9;279(28):29565-71 [PMID: 15123609]
  65. J Microsc. 2006 Dec;224(Pt 3):213-32 [PMID: 17210054]
  66. FEBS Lett. 1992 Apr 27;301(3):282-6 [PMID: 1315694]
  67. J Cataract Refract Surg. 2005 Feb;31(2):412-23 [PMID: 15767167]
  68. Int J Mol Med. 2019 Apr;43(4):1888-1899 [PMID: 30816491]
  69. J Biol Chem. 2004 Aug 27;279(35):37153-62 [PMID: 15210722]
  70. Exp Eye Res. 2001 Aug;73(2):191-202 [PMID: 11446769]
  71. Am J Respir Cell Mol Biol. 2009 Jun;40(6):643-53 [PMID: 18988920]
  72. Invest Ophthalmol Vis Sci. 2005 Feb;46(2):470-8 [PMID: 15671271]
  73. Pharmacol Res Perspect. 2021 Apr;9(2):e00756 [PMID: 33811466]
  74. J Biol Chem. 2021 Jan-Jun;296:100641 [PMID: 33839159]
  75. J Biol Chem. 2012 Jan 2;287(1):712-722 [PMID: 22102283]
  76. Transl Vis Sci Technol. 2020 Mar 30;9(4):29 [PMID: 32818116]
  77. Cell Chem Biol. 2021 Jul 15;28(7):918-933 [PMID: 33974914]
  78. Annu Rev Genet. 1996;30:405-39 [PMID: 8982460]
  79. Invest Ophthalmol Vis Sci. 2014 Jul 01;55(8):4691-9 [PMID: 24985478]
  80. Biochim Biophys Acta. 2004 Nov 29;1695(1-3):89-111 [PMID: 15571811]
  81. Case Rep Ophthalmol. 2014 Jan 07;5(1):6-10 [PMID: 24575032]

Grants

  1. R01 EY028911/NEI NIH HHS

MeSH Term

Humans
Ligands
Signal Transduction
Proto-Oncogene Proteins c-cbl
Proto-Oncogene Proteins c-met
Phosphorylation
Ubiquitination
Immunoblotting

Chemicals

Ligands
Proto-Oncogene Proteins c-cbl
Proto-Oncogene Proteins c-met